Peginterferon beta-1b biosimilar - Pfenex

Drug Profile

Peginterferon beta-1b biosimilar - Pfenex

Alternative Names: PF-726

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Pfenex - Agila Biotech (JV)
  • Developer Pfenex
  • Class Antivirals; Interferons; Polyethylene glycols
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Multiple-sclerosis in USA (Parenteral)
  • 16 Mar 2015 Pfenex terminates its agreement with Stelis Biopharma for Multiple sclerosis
  • 16 Apr 2013 Early research in Multiple sclerosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top